With the first therapeutic cancer vaccine approved by the FDA in April 2010, and other vaccines currently in the pipeline, the interest in this developing area is set to increase exponentially.

Breaking new grounds,Cancer Vaccines provides a state of the art perspective on a projected, rapidly growing field, and describes the successful journey of the first licensed therapeutic vaccines for cancer, from design to approval.

Written and edited by key personnel in industry and academia working within cancer vaccines development, this book is the result of a global collaborative effort integrating industry, academia, non-for profit, with participation from members of regulatory agencies.

Key features:

• Highlights major vaccines and platform technologies in early or late development, nearing approval
• Introduces emerging technologies that could yield novel classes of drugs bridging active and passive immunotherapies
• Provides an update of pipeline and approved cancer vaccines
• Encompasses both scientific, translational as well as development aspects
• Includes an introductory chapter on the immune systems role in cancer and a closing chapter on the challenges involved in cancer vaccine development

An essential read for:

• Cancer immunologists in academia and industry
• Drug developers in the area of oncology biotherapies
• Clinical physicians involved in clinical trials of cancer biotherapies
• Regulatory agencies